{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Acute+Respiratory+Syndrome+Coronavirus+2+%28SARS-CoV-2%29&page=13",
    "query": {
      "condition": "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 1233,
    "total_pages": 124,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Acute+Respiratory+Syndrome+Coronavirus+2+%28SARS-CoV-2%29&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Acute+Respiratory+Syndrome+Coronavirus+2+%28SARS-CoV-2%29&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T16:23:41.370Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06334731",
      "title": "Antimicrobial Resistance During the SARS-CoV-2 (COVID-19) Pandemic",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Methodist Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2021-07-06",
      "completion_date": "2025-07-14",
      "has_results": false,
      "last_update_posted_date": "2025-07-28",
      "last_synced_at": "2026-10-14T16:23:41.370Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06334731"
    },
    {
      "nct_id": "NCT04405739",
      "title": "The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV 2"
      ],
      "interventions": [
        {
          "name": "EIDD-2801",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ridgeback Biotherapeutics, LP",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2020-06-16",
      "completion_date": "2022-02-21",
      "has_results": true,
      "last_update_posted_date": "2023-03-23",
      "last_synced_at": "2026-10-14T16:23:41.370Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Oak Lawn, Illinois + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        },
        {
          "city": "Park Ridge",
          "state": "Illinois"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04405739"
    },
    {
      "nct_id": "NCT04333953",
      "title": "COVID-19 in Patients With HIV",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV/AIDS",
        "COVID-19",
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "No intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Missouri-Columbia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 412,
      "start_date": "2020-04-01",
      "completion_date": "2022-03-28",
      "has_results": false,
      "last_update_posted_date": "2022-05-23",
      "last_synced_at": "2026-10-14T16:23:41.370Z",
      "location_count": 1,
      "location_summary": "Columbia, Missouri",
      "locations": [
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04333953"
    },
    {
      "nct_id": "NCT04415151",
      "title": "Tofacitinib for Treatment of Moderate COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19 Pneumonia"
      ],
      "interventions": [
        {
          "name": "Tofacitinib 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 24,
      "start_date": "2020-10-14",
      "completion_date": "2021-02-28",
      "has_results": true,
      "last_update_posted_date": "2025-03-28",
      "last_synced_at": "2026-10-14T16:23:41.370Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04415151"
    },
    {
      "nct_id": "NCT04854980",
      "title": "Serologic Response to the SARS-CoV-2 (COVID-19) MRNA-1273 Vaccine in Select Subsets of Oncology Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Covid19",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Blood Sample",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 8,
      "start_date": "2021-08-03",
      "completion_date": "2024-07-23",
      "has_results": false,
      "last_update_posted_date": "2025-03-30",
      "last_synced_at": "2026-10-14T16:23:41.370Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04854980"
    },
    {
      "nct_id": "NCT04169542",
      "title": "Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Ductal Carcinoma In Situ",
        "COVID-19 Infection",
        "Hereditary Breast Carcinoma",
        "Invasive Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 600,
      "start_date": "2019-05-21",
      "completion_date": "2028-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-10-14T16:23:41.370Z",
      "location_count": 4,
      "location_summary": "Conroe, Texas • Houston, Texas • League City, Texas + 1 more",
      "locations": [
        {
          "city": "Conroe",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "League City",
          "state": "Texas"
        },
        {
          "city": "Sugar Land",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04169542"
    },
    {
      "nct_id": "NCT04666441",
      "title": "COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "REGN10933+REGN10987 combination therapy",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1149,
      "start_date": "2020-12-15",
      "completion_date": "2021-09-21",
      "has_results": true,
      "last_update_posted_date": "2022-04-08",
      "last_synced_at": "2026-10-14T16:23:41.370Z",
      "location_count": 57,
      "location_summary": "Mesa, Arizona • Tucson, Arizona • Canoga Park, California + 48 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04666441"
    },
    {
      "nct_id": "NCT04957082",
      "title": "Culturally-Targeted COVID-19 Communication and SARS-CoV-2 Antibody Testing Evaluation and Uptake",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "SARS-CoV2 Infection"
      ],
      "interventions": [
        {
          "name": "Culturally Targeted SARS-CoV-2 Communication",
          "type": "BEHAVIORAL"
        },
        {
          "name": "General SARS-CoV-2 Communication",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Michigan State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 666,
      "start_date": "2021-08-04",
      "completion_date": "2022-12-19",
      "has_results": true,
      "last_update_posted_date": "2024-06-28",
      "last_synced_at": "2026-10-14T16:23:41.370Z",
      "location_count": 1,
      "location_summary": "Flint, Michigan",
      "locations": [
        {
          "city": "Flint",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04957082"
    },
    {
      "nct_id": "NCT05037097",
      "title": "A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "SARS-CoV-2 Infection",
        "Corona Virus Infection"
      ],
      "interventions": [
        {
          "name": "ARCT-165",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ARCT-154",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ARCT-021",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Arcturus Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 72,
      "start_date": "2021-08-30",
      "completion_date": "2023-12-19",
      "has_results": true,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-10-14T16:23:41.370Z",
      "location_count": 2,
      "location_summary": "Wichita, Kansas • Kansas City, Missouri",
      "locations": [
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05037097"
    },
    {
      "nct_id": "NCT04729140",
      "title": "An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Ivermectin Tablets",
          "type": "DRUG"
        },
        {
          "name": "Doxycycline Tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Max Health, Subsero Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2020-12-28",
      "completion_date": "2022-03-28",
      "has_results": false,
      "last_update_posted_date": "2021-04-01",
      "last_synced_at": "2026-10-14T16:23:41.370Z",
      "location_count": 1,
      "location_summary": "Sarasota, Florida",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04729140"
    }
  ]
}